Pegylated interferon for the treatment of early myelofibrosis: correlation of serial laboratory stud...
Pegylated interferon for the treatment of early myelofibrosis: correlation of serial laboratory studies with response to therapy
About this item
Full title
Author / Creator
Publisher
Berlin/Heidelberg: Springer Berlin Heidelberg
Journal title
Language
English
Formats
Publication information
Publisher
Berlin/Heidelberg: Springer Berlin Heidelberg
Subjects
More information
Scope and Contents
Contents
Pegylated interferon α-2a (Peg-IFN) has been shown to induce hematologic and molecular responses in patients with the Philadelphia-negative myeloproliferative neoplasms (MPNs), including polycythemia vera (PV) and essential thrombocythemia (ET). We describe a series of patients with long-standing MPNs among whom Peg-IFN was initiated when they deve...
Alternative Titles
Full title
Pegylated interferon for the treatment of early myelofibrosis: correlation of serial laboratory studies with response to therapy
Authors, Artists and Contributors
Identifiers
Primary Identifiers
Record Identifier
TN_cdi_proquest_miscellaneous_1777979052
Permalink
https://devfeature-collection.sl.nsw.gov.au/record/TN_cdi_proquest_miscellaneous_1777979052
Other Identifiers
ISSN
0939-5555
E-ISSN
1432-0584
DOI
10.1007/s00277-016-2631-0
